title: Targeting human dendritic cells in situ to improve vaccines.
abstract: Dendritic cells (DCs) provide a critical link between innate and adaptive immunity. The potent antigen presenting properties of DCs makes them a valuable target for the delivery of immunogenic cargo. Recent clinical studies describing in situ DC targeting with antibody-mediated targeting of DC receptor through DEC-205 provide new opportunities for the clinical application of DC-targeted vaccines. Further advances with nanoparticle vectors which can encapsulate antigens and adjuvants within the same compartment and be targeted against diverse DC subsets also represent an attractive strategy for targeting DCs. This review provides a brief summary of the rationale behind targeting dendritic cells in situ, the existing pre-clinical and clinical data on these vaccines and challenges faced by the next generation DC-targeted vaccines.
authors: Department of Medicine, Yale University, New Haven, CT, United States.
authors: Kartik
authors: K
authors: Sehgal
authors: Pediatrics, Yale University, New Haven, CT, United States.
authors: Kavita M
authors: KM
authors: Dhodapkar
authors: Department of Medicine, Yale University, New Haven, CT, United States. Electronic address: madhav.dhodapkar@yale.edu.
authors: Madhav V
authors: MV
authors: Dhodapkar
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology; D017951:Antigen Presentation / Q000276:immunology; D000938:Antigen-Presenting Cells / Q000276:immunology / Q000378:metabolism; D000941:Antigens / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D051379:Mice; D053758:Nanoparticles; D010641:Phenotype; D014612:Vaccines / Q000276:immunology*
chemical_list: D000906:Antibodies; D000941:Antigens; D014612:Vaccines
keywords: Dendritic cell; Nanoparticles; Targeted vaccines